Compare HUIZ & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HUIZ | TCRX |
|---|---|---|
| Founded | 2006 | 2018 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.6M | 11.8M |
| IPO Year | 2019 | 2021 |
| Metric | HUIZ | TCRX |
|---|---|---|
| Price | $2.10 | $0.15 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $1.00 |
| AVG Volume (30 Days) | 25.4K | ★ 420.2K |
| Earning Date | 08-20-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 12.28 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $10,325,000.00 |
| Revenue This Year | $6.27 | N/A |
| Revenue Next Year | $11.13 | N/A |
| P/E Ratio | $7.81 | ★ N/A |
| Revenue Growth | N/A | ★ 266.65 |
| 52 Week Low | $1.04 | $0.14 |
| 52 Week High | $3.83 | $1.47 |
| Indicator | HUIZ | TCRX |
|---|---|---|
| Relative Strength Index (RSI) | 49.77 | 31.39 |
| Support Level | $1.52 | N/A |
| Resistance Level | $2.16 | $0.21 |
| Average True Range (ATR) | 0.17 | 0.02 |
| MACD | -0.04 | 0.00 |
| Stochastic Oscillator | 27.66 | 8.07 |
Huize Holding Ltd is an independent online insurance product and service platform in China. The company distributes on its platform insurance products underwritten by the insurance companies that cooperate with the company, which the company refers to as its insurer partners, and helps them reach a large number of insurance clients. The company's platform offers a digitalized insurance purchase experience and services through various internet and mobile internet channels. The company generates revenues from the insurance brokerage fees paid by its insurer partners. Geographically, the company is concentrated in PRC Mainland, Hong Kong and others segments.
TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.